Baldessarini, R. Drugs and the treatment of psychiatric disorders. Goodman & Gilman's The Pharmacological Basis of Therapeutics 9th Edition. Hardman et al. eds. 1996 p. 399 and Ch 18: 431-459, McGraw-Hill New York. |
Blum et al., 1995, Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour. Pharmacogenetics 5:121-141. |
Bray, 2000, A concise review on the therapeutics of obesity. Nutrition 16:953-960. |
Crown W. Economic outcomes associated with tricyclic antidepressant and selective serotonin reuptake inhibitor treatments for depression. Acta Psychiatr Scand Suppl. 2000;403:62-6. |
D'Aquila et al., 2000, The role of dopamine in the mechanism of action of antidepressant drugs. Eur. J. Pharmacol. 405:365-373. |
Epstein et al., 1981, 1-Aryl-3-azabicyclo[3.1.0]hexanes, a new series of nonnarcotic analgesic agents. J Med Chem. 24(5):481-90. |
Frazer, 2000, Norepinephrine involvement in antidepressant action. J. Clin. Psychiatry. 61(10):25-30. |
Fredman et al., 2000, Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current “next-step” practices. J. Clin. Psychiatry 61(6):403-8. |
Hackh's Chemical Dictionary, 4th Edition, 1969, Julius Grant, ed., McGraw-Hill Book Company, New York, pp. 474-475. |
Harrison's Principles of Internal medicine 2485-2503 (Fauci et al. eds., 14th ed. 1998). |
Hitri et al., 1994, Molecular, functional and biochemical characteristics of the dopamine transporter: regional differences and clinical relevance. Clin. Pharmacol. 17:1-22. |
Hoffman et al., 1998, Localization and dynamic regulation of biogenic amine transporters in the mammalian central nervous system. Front. Neuroendocrinol. 19(3):187-231. |
Kiyatkin, 1994, Dopamine mechanisms of cocaine addiction. Int. J. Neurosci. 78:75-101. |
Kreek, 1996, Cocaine, dopamine and the endogenous opioid system. J. Addict. Dis. 15:73-96. |
Leonhardt et al., 1999, New approaches in the pharmacological treatment of obesity. Eur. J. Nutr. 38:1-13. |
Meyerson et al., 1987, Allosteric interaction between the site labeled by [3H]imipramine and the serotonin transporter in human platelets. J. Neurochem. 48(2):560-5. |
Nagatsu et al., 2000, Changes in cytokines and neurotrophins in Parkinson's disease. J. Neural Transm. Suppl. 60:277-290. |
Noble, 1994, Polymorphisms of the D2 dopamine receptor gene and alcoholism and other substance use disorders. Alcohol Supp. 2:35-43. |
Scates et al., 2000, Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression. Ann. Pharmacother. 34(11):1302-12. |
Simon et al., 1999, TCAs or SSRIs as initial therapy for depression? J. of Family Practice. 48:845-6. |
Stacy et al., 1996, Treatment options for early Parkinson's disease. Am. Fam. Phys. 53:1281-1287. |
Sullivan et al., 1985, “Mechanisms of Appetite Modulation By Drugs,” Federation Proceedings, vol. 44, No. 1, Part 1, pp. 139-144. |
Wong et al., 2000, Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol. Psychiatry. 47(9):818-29. |